UPDATE: Citi Upgrades Spark Therapeutics (ONCE) to Buy, Sees M&A Value Upwards of $130/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Wall St set to open lower as Meta Platforms, economic data weigh
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- US dollar briefly falls vs yen after GDP data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- Meta Platforms, IBM, Caterpillar fall premarket; American Airlines, Chipotle rise
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
Spark Therapeutics (ONCE) PT Lowered to $77 at Barclays
August 8, 2018 5:11 AM EDTBarclays lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $77.00 (from $85.00) while maintaining a Overweight rating.
... MoreBMO Capital Downgrades Spark Therapeutics (ONCE) to Market Perform
August 7, 2018 4:23 PM EDTBMO Capital downgraded Spark Therapeutics (NASDAQ: ONCE) from Outperform to Market Perform with a price target of $60.00 (from $98.00).
For an analyst ratings summary and ratings history on Spark Therapeutics click here. For more ratings news on Spark Therapeutics click here.
Shares of Spark Therapeutics closed at $77.61 yesterday.
... MoreSpark Therapeutics (ONCE) PT Lowered to $61 at SunTrust Robinson Humphrey
August 7, 2018 3:32 PM EDTSunTrust Robinson Humphrey lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $61.00 (from $102.00) while maintaining a Buy rating.
Analsyt Edward Nash commented, "Updated data from hemophilia A program dims outlook as shares tumble 28% intraday (vs S&P50 up 0.3%). While the mean... More
Spark Therapeutics (ONCE) PT Lowered to $80 at Cowen
August 7, 2018 3:31 PM EDTCowen lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $80.00 (from $90.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Spark reported Q2 financials and provided an update on the SPK-8011 clinical program. Five of seven patients treated with... More
Spark Therapeutics (ONCE) PT Lowered to $64 at RBC Capital
August 7, 2018 2:31 PM EDTRBC Capital lowered its price target on Spark Therapeutics (NASDAQ: ONCE) to $64.00 (from $75.00) while maintaining a Sector Perform rating.
Analyst Kennen MacKay said the view today's SPK-8011 update suggestive of efficacy and safety below investor expectations and expect the stock to be choppy into ASH data detailing today's update.
... More
